Back to CL
CL Stock Analysis: Valuation, Dividend and Outlook
$CLNEUTRALHousehold & Personal Products

CL Stock Analysis: Valuation, Dividend and Outlook

Colgate-Palmolive’s defensive brands and cash generation support its steady profile, while a recent earnings beat adds a positive data point. At $99.67, however, the shares sit close to their 52-week high and the supplied analyst mean target, so valuation, margins and execution are key considerations.

November 14, 202610 min read
Current Price
$99.67
+1.81%
Analyst Rating
Strong Buy
Price Target
$101.30
1.6% upside
P/E Ratio
38.72

Executive Summary

Investment Thesis: Colgate-Palmolive pairs essential household and personal-care products with globally recognized brands, recurring demand and substantial free cash flow. Its latest reported quarter beat the supplied EPS estimate, and analysts’ stated consensus is Strong Buy, although the recommendation counts include a meaningful number of Hold ratings and one Strong Sell. At $99.67, CL trades near its 52-week high, with just 1.6% implied upside to the supplied $101.30 mean target, while a trailing P/E of 38.72 leaves little room for execution setbacks. The overall picture is mixed rather than one-sided.

Current Price: $99.67, as of Friday, November 13 | Key Metric: 2.12% dividend yield | Stance: NEUTRAL

Company Overview

Colgate-Palmolive sells oral-care, personal-care, home-care and pet-nutrition products in markets around the world. Its portfolio includes daily-use products, which can support repeat purchases and relatively resilient demand when consumers reduce discretionary spending.

Key Products & Competitive Position

  • Core Business: Oral care is a central business, alongside personal care, home care and Hill’s pet nutrition.
  • Key Products: Colgate toothpaste and toothbrushes, Palmolive soaps and detergents, elmex and meridol oral-care products, Tom’s of Maine, EltaMD and Hill’s pet food.
  • Competitive Moat: Brand recognition, distribution relationships, product breadth and repeat-purchase behavior help the company defend shelf space and maintain customer familiarity.

Recent Developments

The supplied news coverage focuses largely on comparisons with other consumer companies and broader staples-sector pressures, rather than a new company-specific strategic announcement. Coverage highlights CL’s defensive cash-flow profile, while also noting cost pressures and changing consumer trends affecting the sector. Investors tracking the business can watch for evidence that product innovation, premium offerings and pricing are supporting volumes as well as sales dollars; the supplied data does not quantify those factors for the latest quarter.

Financial Snapshot

Market Cap$79.23B
P/E Ratio38.72
52-Week Range$75.96 - $101.18
Dividend Yield2.12%
EPS (TTM)$2.57
ROE1,135.82%*

*ROE differs materially across supplied data snapshots: one reports 1,135.82%, while the Yahoo Finance extract reports 231.74%. Both figures are unusually high and should be interpreted cautiously because very small reported book equity can inflate the ratio.

Revenue & Earnings Trends

The supplied company data lists revenue of approximately $21.28 billion, revenue growth of 4.6% and earnings growth of 3.3%. Gross margin is reported at 60.64%, with a 9.65% profit margin. Those figures suggest a profitable business with meaningful gross margins, but growth is moderate rather than rapid. The most recent reported quarter, dated October 30, 2026, delivered EPS of $0.97 versus an estimate of $0.926, a beat of about 4.8%.

Cash generation is a notable strength: reported operating cash flow is $4.37 billion and free cash flow is $3.37 billion. These figures offer context for the dividend and ongoing investment needs, but a single snapshot cannot establish whether the recent growth rate or margins are sustainable.

Balance Sheet Highlights

Reported cash is $1.61 billion against total debt of $7.72 billion, and the current ratio is 0.96, below 1.0. The quick ratio is lower at 0.53, indicating limited coverage of current liabilities by cash and other quick assets. Consumer-staples companies can operate with working-capital ratios below 1, but these figures still make cash conversion, debt servicing and access to capital important monitoring points.

The supplied debt-to-equity ratio is 1,205.62%, another unusually high figure that may be amplified by a small equity base. Data vendors also disagree on several balance-sheet and profitability measures. The ratios are therefore best treated as warning flags to investigate in company filings, not as precise standalone measures of financial distress.

Valuation Analysis

Current Valuation Metrics

Forward P/E24.3Industry comparison not supplied
PEG Ratio1.79Growth-adjusted
EV/EBITDA16.75-year comparison not supplied
P/S Ratio3.7Peer comparison not supplied

The forward P/E uses the supplied forward EPS of $4.10, while the trailing P/E is 38.72 based on TTM EPS of $2.57. That gap makes the earnings outlook important: if forecast earnings do not materialize, the apparent forward multiple would be less informative. Market capitalization divided by reported revenue implies a price-to-sales ratio of about 3.7; the supplied enterprise-value-to-revenue figure is 3.96.

Historical Comparison

A reliable five-year valuation average was not included in the supplied information, so a precise historical premium or discount cannot be established here. The available two-year price data shows an average close of $85.95 and a 14.3% total return, while the stock’s supplied 52-week change is 27.7%. Those price statistics provide context but do not substitute for a matched historical earnings-multiple comparison.

Fair Value Estimate

The supplied analyst mean target is $101.30, about 1.6% above the Friday, November 13 reference price. Analysts’ target range is wide, and a separate data extract lists a $101.70 mean and an $88 low rather than the supplied $95 low. On the available evidence, the share price appears close to the central analyst estimate, while a premium trailing multiple makes the valuation sensitive to earnings delivery, volume trends and interest-rate expectations. A precise discounted-cash-flow estimate would require assumptions about long-term growth, margins, capital spending and discount rates that were not provided.

Competitive Landscape

Market Position

Market Share: Exact current share not supplied | Ranking: Leading global toothpaste brand, based on the company’s established market positioning

Key Competitors

Procter & Gamble (PG)Procter & Gamble competes across oral care and numerous household and personal-care categories.
Kimberly-Clark (KMB)Kimberly-Clark sells personal-care and tissue products, including brands in adjacent consumer staples markets.
$CHDChurch & Dwight competes in oral care, personal care and household products.

Competitive Advantages

  • Brand Recognition: Familiar brands can encourage repeat purchases and support distribution across a broad range of markets.
  • Global Reach: A diversified geographic footprint gives CL exposure to different consumer markets, though it also brings currency and local-market risks.
  • Everyday Demand: Toothpaste, soap and pet food are recurring-use products, which can make demand less cyclical than that for discretionary goods.

Earnings Track Record

Last 4 Quarters: 1 confirmed beat / 0 confirmed misses

The supplied data confirms only the latest quarter. It does not provide comparable actual-versus-estimate results for the other three quarters, so the count above is not a complete four-quarter record.

Recent Earnings History

Q3 2026$0.97 vs $0.926 estBEAT
Q2 2026Actual and estimate not suppliedN/A
Q1 2026Actual and estimate not suppliedN/A
Q4 2025Actual and estimate not suppliedN/A

Guidance Trend

No management guidance revisions were included in the supplied material. The next listed report is expected January 29, 2027, with estimated EPS of $0.98. That estimate is a market expectation, not company guidance; the next report’s revenue, organic sales, volume and margin commentary will help determine whether the recent beat reflects durable operating progress.

Analyst Sentiment

Consensus Rating: Strong Buy, as reported in the supplied analyst data

Strong Buy: 6 Buy: 7 Hold: 7 Sell: 0 Strong Sell: 1

The 21 supplied ratings include 13 Buy or Strong Buy calls, seven Holds and one Strong Sell. A separate Yahoo Finance extract reports a Buy recommendation based on 20 analyst opinions, underscoring that vendor counts and consensus labels can vary with timing and methodology.

Price Targets

  • Low: $95
  • Mean: $101.30 (+1.6% upside)
  • High: $112

Recent Analyst Actions

No specific recent upgrades, downgrades or price-target changes were supplied. The Strong Buy consensus is therefore a snapshot, not evidence of a recent change in analyst opinion. Target feeds also differ: one extract reports a $101.70 mean, a $112 high and an $88 low, so readers should confirm the date and provider behind any target they use.

Recent News & Catalysts

Key Developments

  • Defensive staples profile: November 13 coverage compared CL’s steadier cash flows with Celsius’s faster growth in functional energy. The comparison highlights differing growth and risk profiles, rather than a new CL operating announcement.
  • Rates and dividend stocks: Another November 13 article discussed how a possible December rate increase could affect dividend-paying companies, including a toothpaste maker. Higher rates can increase the relative appeal of fixed-income alternatives and affect valuation multiples.
  • Sector execution pressures: November 12 coverage identified CL among consumer-staples companies navigating cost pressures and changing consumer trends. The relevant company-level tests are volume, pricing, mix and margin performance, which were not detailed in the supplied article summary.

Upcoming Catalysts

Next Earnings: January 29, 2027, expected | Key Events: Q4 results, full-year outlook, organic sales and volume trends, input costs, pricing, margins and dividend coverage

As of Saturday, November 14, U.S. stock markets are closed. The next regular trading session is Monday, November 16. The next listed earnings event is more than two months away, so updates to inflation, interest-rate expectations and consumer-staples demand may shape sentiment in the interim.

Technical Outlook

Current Price: $99.67, Friday, November 13 close reference vs 52-Week High: $101.18 (1.5% below the high)

Trend Analysis

The supplied price is near the top of the 52-week range of $75.96 to $101.18, and the provided 52-week change is positive 27.7%. The two-year data extract reports a 14.3% total return and an $85.95 average close. These indicate a strong recent price advance relative to that average, but moving averages, trading volume and momentum indicators were not provided, limiting the depth of a technical assessment.

Key Levels

  • Resistance: $100 to $101.18, including the recent quoted range high and 52-week high; $112, the supplied analyst high target, is a separate longer-range reference rather than a technical level.
  • Support: Around $98, near the supplied Friday range low of $98.05; $95, the supplied analyst low target, is another reference, not verified chart support.

Bull vs Bear Case

Bull Case

  • Resilient demand: Everyday oral-care, personal-care and pet-nutrition products can help steady sales through weaker economic periods.
  • Cash generation: Reported free cash flow of $3.37 billion and operating cash flow of $4.37 billion provide financial capacity for dividends and business investment.
  • Earnings delivery: The latest reported EPS beat and 4.6% revenue growth offer evidence of ongoing growth, though more quarterly detail is needed to assess its composition.

Bull Target: $112, the supplied analyst high target, about 12.4% above $99.67

Bear Case

  • Valuation sensitivity: A 38.72 trailing P/E leaves the share price exposed if earnings growth or forecasts disappoint.
  • Margin and cost pressure: Input costs, pricing limits and consumer trade-down could constrain margins or volume growth.
  • Limited central target gap: The supplied $101.30 mean target is only 1.6% above the reference price, while target data varies by provider.

Bear Target: $88, the low target in a separate data extract, about 11.7% below $99.67; the supplied analyst low is $95

The target figures above are analyst estimates and scenarios, not forecasts from this report. The different low targets illustrate the uncertainty in relying on a single consensus feed.

Risks to Consider

  • Valuation Risk: The trailing multiple is high relative to the supplied forward multiple. A slower earnings trajectory could make the current price harder to support.
  • Competitive Risk: CL competes with large, well-funded consumer-products companies and private-label alternatives. Brand strength does not eliminate pressure on pricing, shelf space or product innovation.
  • Macro Risk: Inflation, currency fluctuations, commodity costs and higher interest rates can affect expenses, reported results and investor valuation assumptions.
  • Execution Risk: The company must sustain product relevance and manage costs while protecting volumes. The below-1 current ratio, low quick ratio and inconsistent ROE data also warrant review against reported filings.

Bottom Line

Investment Verdict: NEUTRAL

CL has recognizable brands, recurring product demand and substantial reported cash generation, with its latest supplied EPS result beating estimates. Those strengths are balanced by a premium trailing valuation, limited upside to the supplied mean target, incomplete earnings history and inconsistent vendor figures for ROE and analyst targets. The evidence supports monitoring execution and valuation together, rather than treating either the defensive profile or the analyst consensus as conclusive.

Action Items for Investors

  • Long-term investors: Compare CL’s sales growth, volumes, margins, free cash flow and dividend coverage with its own historical results and relevant peers before drawing conclusions about its fit in a portfolio.
  • Short-term traders: Treat the $98 to $101.18 area as a reference based on the supplied Friday range and 52-week high, not as a guaranteed support or resistance zone. Confirm price and volume data when markets reopen Monday.
  • Risk management: Check primary company filings for current debt, working capital, ROE and dividend details; the supplied data feeds disagree on several measures. Consider how a valuation contraction or earnings shortfall could affect any investment exposure.

What to Watch This Week

  • Monday, November 16 is the next U.S. trading session after the Saturday report date; Friday’s $99.67 price is the latest supplied reference.
  • Follow changes in inflation and December rate expectations, which may influence dividend-stock valuations and consumer costs.
  • Watch for company-specific updates on pricing, volumes, product demand or input costs ahead of the expected January 29, 2027 earnings report.

Disclosure: This report is for informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Market data and analyst estimates can change and may differ by provider.

Share this report

Share this article

Spread the word on social media

Think CL will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.